nach oben

Erschienen in:

16.06.2018 | Original Paper

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas

verfasst von: Kristian W. Pajtler, Ji Wen, Martin Sill, Tong Lin, Wilda Orisme, Bo Tang, Jens-Martin Hübner, Vijay Ramaswamy, Sujuan Jia, James D. Dalton, Kelly Haupfear, Hazel A. Rogers, Chandanamali Punchihewa, Ryan Lee, John Easton, Gang Wu, Timothy A. Ritzmann, Rebecca Chapman, Lukas Chavez, Fredrick A. Boop, Paul Klimo, Noah D. Sabin, Robert Ogg, Stephen C. Mack, Brian D. Freibaum, Hong Joo Kim, Hendrik Witt, David T. W. Jones, Baohan Vo, Amar Gajjar, Stan Pounds, Arzu Onar-Thomas, Martine F. Roussel, Jinghui Zhang, J. Paul Taylor, Thomas E. Merchant, Richard Grundy, Ruth G. Tatevossian, Michael D. Taylor, Stefan M. Pfister, Andrey Korshunov, Marcel Kool, David W. Ellison

Erschienen in: Acta Neuropathologica | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Of nine ependymoma molecular groups detected by DNA methylation profiling, the posterior fossa type A (PFA) is most prevalent. We used DNA methylation profiling to look for further molecular heterogeneity among 675 PFA ependymomas. Two major subgroups, PFA-1 and PFA-2, and nine minor subtypes were discovered. Transcriptome profiling suggested a distinct histogenesis for PFA-1 and PFA-2, but their clinical parameters were similar. In contrast, PFA subtypes differed with respect to age at diagnosis, gender ratio, outcome, and frequencies of genetic alterations. One subtype, PFA-1c, was enriched for 1q gain and had a relatively poor outcome, while patients with PFA-2c ependymomas showed an overall survival at 5 years of > 90%. Unlike other ependymomas, PFA-2c tumors express high levels of OTX2, a potential biomarker for this ependymoma subtype with a good prognosis. We also discovered recurrent mutations among PFA ependymomas. H3 K27M mutations were present in 4.2%, occurring only in PFA-1 tumors, and missense mutations in an uncharacterized gene, CXorf67, were found in 9.4% of PFA ependymomas, but not in other groups. We detected high levels of wildtype or mutant CXorf67 expression in all PFA subtypes except PFA-1f, which is enriched for H3 K27M mutations. PFA ependymomas are characterized by lack of H3 K27 trimethylation (H3 K27-me3), and we tested the hypothesis that CXorf67 binds to PRC2 and can modulate levels of H3 K27-me3. Immunoprecipitation/mass spectrometry detected EZH2, SUZ12, and EED, core components of the PRC2 complex, bound to CXorf67 in the Daoy cell line, which shows high levels of CXorf67 and no expression of H3 K27-me3. Enforced reduction of CXorf67 in Daoy cells restored H3 K27-me3 levels, while enforced expression of CXorf67 in HEK293T and neural stem cells reduced H3 K27-me3 levels. Our data suggest that heterogeneity among PFA ependymomas could have clinicopathologic utility and that CXorf67 may have a functional role in these tumors.

Nur mit Berechtigung zugänglich

Alexander T, Nolte C, Krumlauf R (2009) Hox genes and segmentation of the hindbrain and axial skeleton. Annu Rev Cell Dev Biol 25:431–456. https://doi.org/10.1146/annurev.cellbio.042308.113423 CrossRefPubMed

Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D et al (2016) Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 8:366ra161. https://doi.org/10.1126/scitranslmed.aah6904 CrossRefPubMedPubMedCentral

Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M et al (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24:660–672. https://doi.org/10.1016/j.ccr.2013.10.006 CrossRefPubMed

Bouffet E, Tabori U, Huang A, Bartels U (2009) Ependymoma: lessons from the past, prospects for the future. Childs Nerv Syst 25:1383–1384. https://doi.org/10.1007/s00381-009-0915-6 CrossRefPubMed

Boulay G, Awad ME, Riggi N, Archer TC, Iyer S, Boonseng WE et al (2017) OTX2 activity at distal regulatory elements shapes the chromatin landscape of group 3 medulloblastoma. Cancer Discov 7:288–301. https://doi.org/10.1158/2159-8290.CD-16-0844 CrossRefPubMedPubMedCentral

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000 CrossRefPubMedPubMedCentral

Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V et al (2002) Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 86:929–939CrossRefPubMedPubMedCentral

Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E et al (2014) Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 134:1112–1122. https://doi.org/10.1002/ijc.28440 CrossRefPubMed

Di Giovannantonio LG, Di Salvio M, Omodei D, Prakash N, Wurst W, Pierani A et al (2014) Otx2 cell-autonomously determines dorsal mesencephalon versus cerebellum fate independently of isthmic organizing activity. Development 141:377–388. https://doi.org/10.1242/dev.102954 CrossRefPubMed

10.

Dosztanyi Z, Csizmok V, Tompa P, Simon I (2005) IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21:3433–3434. https://doi.org/10.1093/bioinformatics/bti541 CrossRefPubMed

11.

Dosztanyi Z, Meszaros B, Simon I (2009) ANCHOR: web server for predicting protein binding regions in disordered proteins. Bioinformatics 25:2745–2746. https://doi.org/10.1093/bioinformatics/btp518 CrossRefPubMedPubMedCentral

12.

Dyer S, Prebble E, Davison V, Davies P, Ramani P, Ellison D et al (2002) Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 161:2133–2141CrossRefPubMedPubMedCentral

13.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:l1. https://doi.org/10.1126/scisignal.2004088 CrossRef

14.

Gessi M, Capper D, Sahm F, Huang K, von Deimling A, Tippelt S et al (2016) Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol 132:635–637. https://doi.org/10.1007/s00401-016-1608-3 CrossRefPubMed

15.

Gessi M, Gielen GH, Dreschmann V, Waha A, Pietsch T (2015) High frequency of H3F3A (K27 M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord. Acta Neuropathol 130:435–437. https://doi.org/10.1007/s00401-015-1463-7 CrossRefPubMed

16.

Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA et al (2012) Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 124:247–257. https://doi.org/10.1007/s00401-012-0981-9 CrossRefPubMedPubMedCentral

17.

Hirate Y, Okamoto H (2006) Canopy1, a novel regulator of FGF signaling around the midbrain–hindbrain boundary in zebrafish. Curr Biol 16:421–427. https://doi.org/10.1016/j.cub.2006.01.055 CrossRefPubMed

18.

Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V et al (2014) Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol 127:731–745. https://doi.org/10.1007/s00401-013-1212-8 CrossRefPubMed

19.

Huang YJ, Acton TB, Montelione GT (2014) DisMeta: a meta server for construct design and optimization. Methods Mol Biol 1091:3–16. https://doi.org/10.1007/978-1-62703-691-7_1 CrossRefPubMedPubMedCentral

20.

Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS et al (2015) Orchestrating high-throughput genomic analysis with bioconductor. Nat Methods 12:115–121. https://doi.org/10.1038/nmeth.3252 CrossRefPubMedPubMedCentral

21.

Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V et al (2016) Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29:379–393. https://doi.org/10.1016/j.ccell.2016.02.001 CrossRefPubMed

22.

Joyon N, Tauziede-Espariat A, Alentorn A, Giry M, Castel D, Capelle L et al (2017) K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol 43:271–276. https://doi.org/10.1111/nan.12329 CrossRefPubMed

23.

Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T et al (2012) Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Societe Francaise d’Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 18:2001–2011. https://doi.org/10.1158/1078-0432.CCR-11-2489 CrossRefPubMed

24.

Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M et al (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28:3182–3190. https://doi.org/10.1200/JCO.2009.27.3359 CrossRefPubMed

25.

Ma X, Wang J, Wang J, Ma CX, Gao X, Patriub V et al (2017) The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis. Oncotarget 8:4062–4078. https://doi.org/10.18632/oncotarget.13270 PubMedCrossRef

26.

Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X et al (2018) Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature 553:101–105. https://doi.org/10.1038/nature25169 CrossRefPubMed

27.

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445–450. https://doi.org/10.1038/nature13108 CrossRefPubMedPubMedCentral

28.

McGuire CS, Sainani KL, Fisher PG (2009) Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg 110:725–729. https://doi.org/10.3171/2008.9.JNS08117 CrossRefPubMed

29.

Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B et al (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12:2070–2079. https://doi.org/10.1158/1078-0432.CCR-05-2363 CrossRefPubMed

30.

Micci F, Panagopoulos I, Bjerkehagen B, Heim S (2006) Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 66:107–112. https://doi.org/10.1158/0008-5472.CAN-05-2485 CrossRefPubMed

31.

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 133:5–12. https://doi.org/10.1007/s00401-016-1643-0 CrossRefPubMed

32.

Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743. https://doi.org/10.1016/j.ccell.2015.04.002 CrossRefPubMedPubMedCentral

33.

Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705–714. https://doi.org/10.1007/s00401-017-1752-4 CrossRefPubMed

34.

Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y et al (2014) C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506:451–455. https://doi.org/10.1038/nature13109 CrossRefPubMedPubMedCentral

35.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA et al (2017) Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23:493–500. https://doi.org/10.1038/nm.4296 CrossRefPubMedPubMedCentral

36.

Puelles E, Acampora D, Lacroix E, Signore M, Annino A, Tuorto F et al (2003) Otx dose-dependent integrated control of antero-posterior and dorso-ventral patterning of midbrain. Nat Neurosci 6:453–460. https://doi.org/10.1038/nn1037 CrossRefPubMed

37.

Punchihewa C, Lee R, Lin T, Orisme W, Dalton J, Aronica E et al (2014) Pediatric posterior fossa ependymomas consist of two molecular subgroups defined by gene expression and methylation profiling. Neuro Oncol 16:011

38.

Raybaud C (2016) MR assessment of pediatric hydrocephalus: a road map. Childs Nerv Syst 32:19–41. https://doi.org/10.1007/s00381-015-2888-y CrossRefPubMed

39.

Raybaud C, Ramaswamy V, Taylor MD, Laughlin S (2015) Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. Childs Nerv Syst 31:1661–1676. https://doi.org/10.1007/s00381-015-2834-z CrossRefPubMed

40.

Rodriguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG (2009) Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the surveillance, epidemiology, and end results (SEER) database (1973–2005). J Surg Res 156:340–351. https://doi.org/10.1016/j.jss.2009.04.024 CrossRefPubMed

41.

Ryall S, Guzman M, Elbabaa SK, Luu B, Mack SC, Zapotocky M et al (2017) H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Childs Nerv Syst 33:1047–1051. https://doi.org/10.1007/s00381-017-3481-3 CrossRefPubMed

42.

Sgaier SK, Lao Z, Villanueva MP, Berenshteyn F, Stephen D, Turnbull RK et al (2007) Genetic subdivision of the tectum and cerebellum into functionally related regions based on differential sensitivity to engrailed proteins. Development 134:2325–2335. https://doi.org/10.1242/dev.000620 CrossRefPubMedPubMedCentral

43.

Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O et al (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92–107. https://doi.org/10.1038/nrc3655 CrossRefPubMedPubMedCentral

44.

Swanson WJ, Vacquier VD (2002) The rapid evolution of reproductive proteins. Nat Rev Genet 3:137–144. https://doi.org/10.1038/nrg733 CrossRefPubMed

45.

Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177. https://doi.org/10.1038/modpathol.3800999 CrossRefPubMed

46.

U-King-Im J, Taylor MD, Raybaud C (2010) Posterior fossa ependymomas: new radiological classification with surgical correlation. Childs Nerv Syst 26:1765–1772. https://doi.org/10.1007/s00381-010-1251-6 CrossRefPubMed

47.

Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347:394. https://doi.org/10.1126/science.1260419 CrossRef

48.

van der Maaten L, Hinton G (2008) Visualizing data using t-SNE. J Mach Learn Res 9:2579–2605

49.

Vinchon M, Leblond P, Noudel R, Dhellemmes P (2005) Intracranial ependymomas in childhood: recurrence, reoperation, and outcome. Childs Nerv Syst 21:221–226CrossRefPubMed

50.

Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison DW, Gilbertson R et al (2012) A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123:727–738. https://doi.org/10.1007/s00401-012-0941-4 CrossRefPubMedPubMedCentral

51.

Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572–1573. https://doi.org/10.1093/bioinformatics/btq170 CrossRefPubMedPubMedCentral

52.

Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143–157. https://doi.org/10.1016/j.ccr.2011.07.007 CrossRefPubMedPubMedCentral

53.

Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444–450. https://doi.org/10.1038/ng.2938 CrossRefPubMedPubMedCentral

54.

Xue B, Dunbrack RL, Williams RW, Dunker AK, Uversky VN (2010) PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta 1804:996–1010. https://doi.org/10.1016/j.bbapap.2010.01.011 CrossRefPubMedPubMedCentral

55.

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612. https://doi.org/10.1038/ng.2611 CrossRefPubMedPubMedCentral

Titel: Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
verfasst von: Kristian W. Pajtler
Ji Wen
Martin Sill
Tong Lin
Wilda Orisme
Bo Tang
Jens-Martin Hübner
Vijay Ramaswamy
Sujuan Jia
James D. Dalton
Kelly Haupfear
Hazel A. Rogers
Chandanamali Punchihewa
Ryan Lee
John Easton
Gang Wu
Timothy A. Ritzmann
Rebecca Chapman
Lukas Chavez
Fredrick A. Boop
Paul Klimo
Noah D. Sabin
Robert Ogg
Stephen C. Mack
Brian D. Freibaum
Hong Joo Kim
Hendrik Witt
David T. W. Jones
Baohan Vo
Amar Gajjar
Stan Pounds
Arzu Onar-Thomas
Martine F. Roussel
Jinghui Zhang
J. Paul Taylor
Thomas E. Merchant
Richard Grundy
Ruth G. Tatevossian
Michael D. Taylor
Stefan M. Pfister
Andrey Korshunov
Marcel Kool
David W. Ellison
Publikationsdatum: 16.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Acta Neuropathologica / Ausgabe 2/2018
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-018-1877-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile

Heterogeneity within the PF-EPN-B ependymoma subgroup

FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma

HEIRECA! The HEIdelberg REvolution of CAncer classification and what it means for neurooncology and neuropathology

Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations